# Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma

> **NCT01405573** · PHASE3 · TERMINATED · sponsor: **National Cancer Institute, Naples** · enrollment: 35 (actual)

## Conditions studied

- Advanced Adult Hepatocellular Carcinoma

## Interventions

- **OTHER:** Best Supportive Care
- **DRUG:** sorafenib

## Key facts

- **NCT ID:** NCT01405573
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** lack of enrolment
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01405573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01405573, "Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01405573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*